ReviewWorld journal of gastroenterology2008
Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors.
Review in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Advances in the diagnosis and treatment of MET-variant digestive tract tumors.World journal of gastrointestinal oncology · 2024Review
- High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy.BMC cancer · 2022Article
- Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach.Cancer imaging : the official publication of the International Cancer Imaging Society · 2021Article
- CXCL12 gene silencing down-regulates metastatic potential via blockage of MAPK/PI3K/AP-1 signaling pathway in colon cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Article
- Phosphorylated CXCR4 expression has a positive prognostic impact in colorectal cancer.Cellular oncology (Dordrecht, Netherlands) · 2017Article
- Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.Journal of cancer research and clinical oncology · 2017Article
- SDF-1/CXCR7 axis regulates the proliferation, invasion, adhesion, and angiogenesis of gastric cancer cells.World journal of surgical oncology · 2016Article
- Enhancement of T cell recruitment and infiltration into tumours.Clinical and experimental immunology · 2014Review
- High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma.World journal of surgical oncology · 2012Article
- The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer.British journal of cancer · 2012Article
- CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.Cancer research · 2011Article
- Evaluation of the combined expression of chemokine SDF-1α and its receptor CXCR4 as a prognostic marker for gastric cancer.Experimental and therapeutic medicine · 2011Article
- The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.The Journal of pathology · 2011Article
- Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal malignancies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011Article
- The role of chemokine receptor CXCR4 in the biologic behavior of human soft tissue sarcoma.Sarcoma · 2011Article
- Cell surface markers in colorectal cancer prognosis.International journal of molecular sciences · 2010Review
- Circulating tumour-derived microvesicles in plasma of gastric cancer patients.Cancer immunology, immunotherapy : CII · 2010Article
- Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer.International journal of cancer · 2010Article
- microRNAs and Corresponding Targets Involved in Metastasis of Colorectal Cancer in PreclinicalCancer genomics & proteomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To review the implication of CXCR4 for gastrointestinal cancer, a "Pubmed" analysis was performed in order to evaluate the relevance of CXCR4 and its ligands for gastrointestinal cancers. Search terms applied were "cancer, malignoma, esophageal, gastric, colon, colorectal, hepatic, pancreatic, CXCR4, SDF-1alpha, and SDF-1beta". CXCR4 expression correlated with dissemination of diverse gastrointestinal malignomas. The CXCR4 ligand SDF-1alpha might act as "chemorepellent" while SDF-1beta might act as "chemorepellent" for CTLs, inducing tumor rejection. The paracrine expression of SDF-1alpha was furthermore closely associated with neoangiogenesis. CXCR4 and its ligands influence the dissemination, immune rejection, and neoangiogenesis of human gastrointestinal cancers. Inhibition of CXCR4 might be an interesting therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.